Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short-term efficacy and safety

Lang, F. M., Teruya, S., Weinsaft, A., Cuomo, M., Santos, A. M., Nalbandian, A., Bampatsias, D., & Maurer, M. S. (2024). Sodium–glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short‐term efficacy and safety. European Journal of Heart Failure, 26(4), 938–947. Portico. https://doi.org/10.1002/ejhf.3198
Authors:
Frederick M Lang
Sergio Teruya
Ariel Weinsaft
Margaret Cuomo
Alfonsina Mirabal Santos
Ani Nalbandian
Dimitrios Bampatsias
Mathew S Maurer
Affiliated Authors:
Frederick M Lang
Sergio Teruya
Ariel Weinsaft
Margaret Cuomo
Alfonsina Mirabal Santos
Ani Nalbandian
Dimitrios Bampatsias
Mathew S Maurer
Columbia Affiliation:
Subjects:
Sodium-Glucose Transporter 2 Inhibitors (MeSH)
Author Keywords:
sglt2 inhibitor
cardiac amyloidosis
transthyretin amyloid
heart failure
preserved ejection fraction
guideline-directed medical therapy
guideline‐directed medical therapy
elink
Publication Type:
Article
Unique ID:
10.1002/ejhf.3198
PMID:
38488292
DOI:
10.1002/ejhf.3198
Journal:
European Journal of Heart Failure
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: